Cancers attributable to tobacco smoking in Italy in 2020.

Attributable fraction Cancer Cigarette smoking Italy Tobacco Tobacco-related cancer

Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
16 Jul 2024
Historique:
received: 22 06 2024
revised: 08 07 2024
accepted: 12 07 2024
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 17 7 2024
Statut: aheadofprint

Résumé

Tobacco smoking is still frequent in Italy and a major cause of cancer globally. We estimated the burden of smoking-related cancer in Italy. To calculate the population attributable fraction (PAF), we adopted a counterfactual scenario for which all individuals never smoked. The PAF of current and former smoking and second-hand smoke (SHS) was estimated for cancers associated with these habits according to the International Agency for Research on Cancer. Relative risk estimates and prevalence of exposure were derived from large-scale studies and national surveys, respectively. A 20-year latency period between exposure and cancer was considered. Cancer incidence data for 2020 and mortality data for 2017 were obtained from the Italian Association of Cancer Registries. Tobacco smoking caused, in men and women respectively, 90.0 % and 58.3 % of lung; 67.8 % and 53.5 % of pharyngeal; 47.0 % and 32.2 % of bladder; 45.9 % and 31.7 % of oral; 36.6 % and 23.6 % of esophageal; 23.0 % and 14.0 % of pancreatic cancer and lower percentages of cancers at other sites. Tobacco smoking accounted for 23.9 % and 7.7 % of new cancer cases in 2020, and 32.1 % and 11.3 % of cancer deaths in 2017 in men and women, respectively, corresponding to 17.3 % of cases and 24.5 % of cancer deaths overall. The PAF of lung cancer due to SHS in never smoking women married with smokers was 13.0 %. Tobacco smoking is a primary cause of cancer in Italy in both sexes. Tobacco control policies are warranted.

Sections du résumé

BACKGROUND BACKGROUND
Tobacco smoking is still frequent in Italy and a major cause of cancer globally. We estimated the burden of smoking-related cancer in Italy.
METHODS METHODS
To calculate the population attributable fraction (PAF), we adopted a counterfactual scenario for which all individuals never smoked. The PAF of current and former smoking and second-hand smoke (SHS) was estimated for cancers associated with these habits according to the International Agency for Research on Cancer. Relative risk estimates and prevalence of exposure were derived from large-scale studies and national surveys, respectively. A 20-year latency period between exposure and cancer was considered. Cancer incidence data for 2020 and mortality data for 2017 were obtained from the Italian Association of Cancer Registries.
RESULTS RESULTS
Tobacco smoking caused, in men and women respectively, 90.0 % and 58.3 % of lung; 67.8 % and 53.5 % of pharyngeal; 47.0 % and 32.2 % of bladder; 45.9 % and 31.7 % of oral; 36.6 % and 23.6 % of esophageal; 23.0 % and 14.0 % of pancreatic cancer and lower percentages of cancers at other sites. Tobacco smoking accounted for 23.9 % and 7.7 % of new cancer cases in 2020, and 32.1 % and 11.3 % of cancer deaths in 2017 in men and women, respectively, corresponding to 17.3 % of cases and 24.5 % of cancer deaths overall. The PAF of lung cancer due to SHS in never smoking women married with smokers was 13.0 %.
CONCLUSIONS CONCLUSIONS
Tobacco smoking is a primary cause of cancer in Italy in both sexes. Tobacco control policies are warranted.

Identifiants

pubmed: 39018889
pii: S1877-7821(24)00102-4
doi: 10.1016/j.canep.2024.102623
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102623

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Auteurs

Giulia Collatuzzo (G)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Matteo Malvezzi (M)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Silvia Mangiaterra (S)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Matteo Di Maso (M)

Department of Clinical Sciences and Community Health, University of Milan, Milan.

Federica Turati (F)

Department of Clinical Sciences and Community Health, University of Milan, Milan.

Fabio Parazzini (F)

Department of Clinical Sciences and Community Health, University of Milan, Milan.

Claudio Pelucchi (C)

Department of Clinical Sciences and Community Health, University of Milan, Milan.

Gianfranco Alicandro (G)

Cystic Fibrosis Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Eva Negri (E)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Carlo La Vecchia (C)

Department of Clinical Sciences and Community Health, University of Milan, Milan.

Paolo Boffetta (P)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA. Electronic address: paolo.boffetta@stonybrookmedicine.edu.

Classifications MeSH